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A B S T R A C T
Therapeutic antibodies have transformed the clinical practice. Not surprisingly, development of antibody thera-
peutics is currently the main focus of the biotechnology industry. Nonetheless, the development process is com-
plex, and many antibodies do not reach the clinic. Reasons for the failures include, undesired binding behavior
(polyreactivity), low stability, poor expression yields, unfavorable pharmacokinetics etc. Numerous studies have
proposed different analytical methods for assessment of physicochemical parameters of antibodies and identifi-
cation of problematic molecules at early stages of the development process. These studies, however, have not
addressed the basic mechanistic question of how sequence features of variable regions determinate the differ-
ent biophysical characteristics and the binding behavior of the antibodies. In a recent study, Jain et al assessed
12 biophysical qualities of 137 monoclonal therapeutic antibodies. We used the raw data from this comprehen-
sive study to perform correlation analyses of different biophysical measurables with various sequence features of
variable regions of the antibodies - number of mutations, length of hypervariable loops, and frequency of amino
acid residue types. The obtained data reveled significant relationships between the sequence characteristics of
the variable domains and different physiochemical properties of antibodies. The data from this study can assist
in design of a set of criteria for early identification of antibodies with developability issues. Moreover, our find-
ings provide novel fundamental insights into the sequence-function relationship of antibodies.
1. Introduction
Antibodies (Abs) are key components of the adaptive immunity.
They link high-fidelity molecular recognition with elicitation of innate
immune reactions. The advent of monoclonal Abs in clinical practice
has had a transformative impact on the therapy of different forms of
cancer and autoimmune diseases. Not surprisingly, at present (March
2019) ca. 80 Abs have been approved for clinical use and hundreds
of Abs are under development by the biotechnology enterprise (Kaplon
and Reichert, 2018a, b). Multiple steps and a high complexity are typ-
ical for the process of development of therapeutic Abs (Steinmeyer and
McCormick, 2008). The final product should meet many extra criteria
in addition to high-affinity recognition of the target antigen. These cri-
teria include: the production yield, the storage stability, the integrity at
high protein concentrations, the antigen-binding promiscuity, the rate
of in vivo clearance etc. Incompliance with any of these hallmarks of
“developability” would make an Ab inappropriate for therapeutic use.
Hence, identification of unfavorable properties of Abs at early stages
of the development process is of uttermost importance (Jarasch et al.,
2015).
In a recent study by Jain et al (T. Jain et al., 2017), 137 mono-
clonal Abs, approved for therapeutic use or that had reached at least
phase 2 in clinical trials, were comprehensively elucidated, using 12
different biophysical and binding assays. These assays have been ap-
plied as a global assessment of the experimental strategies for identifi-
cation of undesirable features of Abs (Avery et al., 2018; Jarasch et al.,
2015; Kelly et al., 2015; Kohli et al., 2015; Liu et al., 2014; Sule et al.,
2011; Xu et al., 2013). Thus, they evaluate Ab attributes that can be
grouped in three broad categories – 1) protein stability; 2) propensity
for aggregation, and 3) antigen binding promiscuity (polyreactivity).
The investigation by Jain et al. (T. Jain et al., 2017) demonstrated that
within the studied repertoire of Abs there are a substantial number of
molecules with undesirable characteristics. This study also showed that
Abs with developability issues belong mainly to a group of molecules
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that have not yet been approved for the clinical use. This observation
validates the feasibility of the comprehensive assessments of the physic-
ochemical features of Abs as a strategy for early identification of mole-
cules inappropriate for clinical use.
Despite unequivocal significance of biophysical parameters of Abs
for evaluation of developability, previous investigations did not system-
atically address an important mechanistic aspect. Especially, how se-
quence features of the variable domains correlate with particular bio-
physical behavior of therapeutic Abs. The experimental data presented
in the study of Jain (T. Jain et al., 2017) and the publicly available se-
quence information of the therapeutic Abs offer an opportunity for ad-
dressing this essential question.
Here we performed correlation analyses between number of muta-
tions in genes encoding V⁠H and V⁠L domains, lengths of CDR loops, and
frequency of particular types of amino acid residues with various physic-
ochemical and binding characteristics of the Abs. We also did molecu-
lar modeling of variable regions of selected Abs with extreme values of
their antigen binding polyreactivity. Presented data reveled important
relationships between sequence of V domains of Abs and their physio-
chemical characteristics and / or polyreactivity. These data would be
valuable for early identification of problematic Abs (based on V re-
gion sequence) as well as for rational improvements of the therapeu-
tic Abs with undesired pharmacological properties. Moreover, the data
from the present analyses contribute to our basic understanding of se-
quence-structure-function relationship in case of Abs.
2. Results and discussion
In their study Jain and colleagues evaluated 12 different physico-
chemical parameters of 137 monoclonal Abs (T. Jain et al., 2017). Some
of these parameters have been also used for the assessment of developa-
bility of other immunoglobulins or scFv fragments (Avery et al., 2018;
Jarasch et al., 2015; Kelly et al., 2015; Kelly et al., 2017; Kohli et al.,
2015; Liu et al., 2014; Sharma et al., 2014; Sule et al., 2011; Xu et al.,
2013). The analyses included estimation of: a) expression titer of Abs
(designated HEK titer); b) thermodynamic stability of Fab (melting tem-
perature, Tm) and accelerated stability (AS-SEC assay); c) hydrophobic-
ity of variable regions (measured by retention of Abs on hydrophobic in-
teraction chromatography columns – HIC and SMAC assays, or measure-
ment of salting out effect – SGAC100); d) propensity of Abs for self-as-
sociation and aggregation (estimation of homophilic IgG interactions -
CSI-BLI and ACSINS assays,); d) off-targets reactivity or polyreactivity
(binding to pooled human IgG - cross-interaction chromatography, CIC
retention time and interaction with unrelated antigens – ELISA, bac-
ulovirus ELISA as well as polyspecificity reagent, PSR, assay).
2.1. Impact of somatic mutations
To figure out the molecular basis of distinct physicochemical quali-
ties of the therapeutic Abs, we first analyzed contribution of number of
somatic mutations in the variable domains. As significant fraction of Abs
in the repertoire (67 out of 137) are humanized, we envisage that amino
acid replacements in CDR loops might not necessarily reflect affinity
maturation process but rather a difference in the sequence of mouse and
human CDR regions. However, we included these Abs in our analyses
because the deviation of the Ab sequence from human germline may im-
pact physiochemical characteristics in similar ways as natural somatic
mutations do.
The estimated average number of amino acid replacement in the
studied repertoire of 137 Abs is 18.6±10.6. The average numbers of
mutations in V⁠H and V⁠L genes are 11.4±6.8 and 7.2±5.2 (mean±SD),
respectively. The number of amino acid replacement in
different Abs varied from 0 to 26, and from 0 to 29 for V⁠H and V⁠L genes
respectively.
Throughout this study we used non-parametric correlation analyses
(Spearman's rank-order correlation). These analyses indicated that the
number of somatic mutations in V⁠H domains had a considerable impact
on different biophysical properties of Abs. Thus, Abs that express high
levels of polyreactivity (PSR and BVP assays), self-reactivity (AC-SINS
and CSI-BLI assays) or cross-reactivity to polyclonal IgG (CIC assay) pos-
sess significantly lower number of somatic mutations in their V⁠H genes
(Fig. 1). On the other hand, the number of somatic mutations in the V⁠L
genes reached statistical significance only in the case of cross-reactivity
to polyclonal IgG (Fig. 2). When we analyzed the total number of muta-
tions (sum of mutations in V⁠H and V⁠L genes for given Ab) the statistical
significance of the correlations observed for V⁠H were retained (Fig. 3).
Further we performed correlation analyses with human (n=57)
and humanized (n=67) Abs, independently. Because of low number
(n=13), the chimeric Abs were excluded from these analyses. The ob-
tained data indicated that the main contributor to the statistical sig-
nificance of the correlation between number of V mutations and anti-
gen-binding polyreactivity is the fraction of humanized Abs (Fig. 3).
Likewise, the fraction of humanized Abs contributed to significant corre-
lation between V region mutations and the self-association of Abs (Fig.
3). However, these data should be interpreted cautiously since the re-
duced number of Abs in each group would decrease the statistical power
of the analyses.
The effect of mutations on antigen binding promiscuity of Abs has
been elucidated in numerous studies. These studies, however, have pro-
vided conflicting conclusions (Dimitrov et al., 2013). Thus, conforma-
tional flexibility and binding promiscuity was associated with absence
or low number of mutations in the V genes (James et al., 2003; Jimenez
et al., 2003, 2004; Manivel et al., 2002, 2000; Nguyen et al., 2003).
Other investigations demonstrated that only a small fraction of B cells
with germline configuration of their V genes (ca. 5%) express polyreac-
tive Abs (Wardemann et al., 2003). However, the percentage of polyre-
active Abs is augmented (up to ca. 20%) following the affinity matura-
tion process (Benckert et al., 2011; T. Tiller et al., 2007). The observed
differences can be reconciled by the fact that there are different mole-
cular mechanisms that determine the polyreactive behavior of Abs (D.
Jain and Salunke, 2019); therefore it is of importance what method is
employed for assessing the polyreactivity. The advantage of data from
study of Jain et al, is that polyreactivity of Abs was assessed by three dif-
ferent techniques, guaranteeing comprehensive evaluation of the phe-
nomenon.
Our results also revealed that low number of somatic mutations in
V⁠H domain is correlated with a higher tendency for self-association of
Abs. Abs that bind themselves (homophilic Abs) have been considered
as a constituent of the natural IgM repertoires in humans and mice
(Kang et al., 1987; Kang and Kohler, 1986; Kaveri et al., 1990). They
usually have non-mutated variable regions. The biological significance
of observation that less mutated Abs are predisposed to high level of ho-
mophilic binding is not clear. One can speculate that self-association of
Abs might result in organization of molecules in higher order clusters,
resulting in antigen recognition with an improved binding avidity, simi-
larly as Fc-mediated hexamerization of IgG (Diebolder et al., 2014). This
would be especially relevant for IgG Abs with low number of somatic
mutations, since they generally have low antigen binding affinity and
lower avidity than IgM.
The mutation status of V⁠L has a lower impact on binding promis-
cuity. Significant positive correlation (p= 0.025, ρ = 0.191) was ob-
served between the number of amino acid replacements in V⁠L genes
and thermodynamic stability of the Fab fragment (expressed as the
melting temperature) (Fig. 2). The significant correlation was also pre
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Fig. 1. Correlation of physicochemical parameters of therapeutic Abs with sequence traits of heavy Ig chain. The heat map displays the values of correlation coefficient (ρ) obtained
after Spearman’s rank-order analysis of the correlation of data from biophysical and antigen binding assays with number of mutations in V regions; the length of CDR H3; or number of
particular amino acid residues in CDR H3. The red signifies positive correlation, the blue negative. The summary of statistical significance is depicted on right panels. The biophysical
parameters are grouped by types – 1) HEKt (expression titer in HEK cells); 2) Tm and AS (measures for Ab stability); 3) ACSINS, CSI (measures for self-association of Abs); 4) CIC (measure
for reactivity to pooled human IgG); 5) PSR, ELISA, BVP (measures for antigen binding polyreactivity of Abs) and 6) SGAC100, HIC, SMAC (measures for hydrophobicity and tendency for
aggregation).
sent when analyses were performed by taking into account the total
number of V genes (sum of V⁠H and V⁠κ or V⁠λ mutations (Fig. 3).
In summary, correlation analyses of data of different physiochemi-
cal properties and binding promiscuity of monoclonal therapeutic Abs,
revealed that lower number of somatic mutations in V genes correlates
with extended binding promiscuity, self-association and decreased ther-
modynamic stability of Fab. As the antigen binding promiscuity and
self-association of Abs have substantial negative impact on pharmacoki-
netics, drug development programs might consider the mutational load
of V genes encoding the therapeutic candidates.
2.2. Length of CDR loops
CDR H3 loop is the most diverse part of the antigen-combining site
of Abs. It also provides the higher number of contact residues for bind-
ing to antigens. (Sundberg and Mariuzza, 2002) The length of CDR H3
may vary significantly in different human Abs (from 6 to 23 amino acid
residues in the studied repertoire, IMGT definition). Therefore, we an-
alyzed how the length of CDR H3 influences different physicochemi-
cal and binding characteristics of Abs. Our correlation analyses showed
that longer CDR H3 was associated with significantly higher hydropho-
bicity (HIC and SMAC assays) (Fig. 1) of Abs. Although the length
of CDR L3 generally varies in narrower range (from 7 to 14 amino
acid residues in the studied repertoire), our analyses revealed that hy
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Fig. 2. Correlation of physicochemical parameters of therapeutic Abs with sequence traits of light Ig chain. The heat map displays the values of correlation coefficient (ρ) obtained after
Spearman’s rank-order analysis of the correlation of data from biophysical and antigen binding assays with number of mutations in V regions; the length of CDR L3; or number of particular
amino acid residues in CDR L3. The red signifies positive correlation, the blue negative. The summary of statistical significance is depicted on right panels.
drophobicity and propensity for aggregation of the therapeutic Abs
is also associated with longer CDR L3 loops (Fig. 2). Interestingly,
the length of CDR L3 also positively correlated with higher reactivity
of monoclonal Abs towards human polyclonal IgG, as determined by
cross-interaction chromatography (Fig. 2).
To the best of our knowledge the length of CDR3 loops has never
been associated with the hydrophobicity and tendency for aggregation
of Abs. The potential explanation of this observation is that the longer
CDR3 loops might provide higher number of surface exposed hydropho-
bic and aromatic residues. It is noteworthy, that Abs generally have
higher than average percentage of surface-exposed aromatic and hy-
drophobic amino acid in their antigen-combining sites as compared to
other proteins or to other regions of the Ab molecule (Mian et al., 1991;
Sundberg and Mariuzza, 2002).
It was suggested that longer CDR H3 loops of human Abs is associ-
ated with a higher degree of polyreactivity (Meffre et al., 2001;
Wardemann et al., 2003). Here we have not found any significant corre-
lation between the size of CDR H3 or other hypervariable loops and the
Ab polyreactivity.
Statistical analyses of the structures of antigen-antibody complexes
demonstrated that both CDR H3 and CDR H2 have the most important
contribution for the interaction with antigen (Robin et al., 2014). This
prompted us to investigate the influence of CDR H2 on the biophysical
and binding qualities of the therapeutic Abs. Interestingly, longer CDR
H2 is associated with significantly lower thermodynamic stability of the
Abs (p= 0.001, ρ = -0.287, Fig. 4).
Taken together our analyses indicate that Abs with long CDR loops
display higher hydrophobicity and concomitantly a higher propensity
for aggregation. Hence, selection of Ab variants with shorter CDR loops
might reduce the risk of failure during the drug development process.
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Fig. 3. Correlation of physicochemical parameters of therapeutic Abs with number of somatic mutations in V genes. The presented results are obtained from integrative analyses of all
antibodies (n=137), from human Abs only (n=57) or from humanized Abs only (n=67). The upper panels depict the results about number of mutations in VH genes, the middle panel –
the number of mutations in VL genes and lower panel – the sum of mutations in VH and VL genes. The heat map displays the values of correlation coefficient (ρ) obtained after Spearman’s
rank-order analysis of the correlation of data from biophysical and antigen binding assays the number of mutations in V regions The red signifies positive correlation, the blue negative.
The summary of statistical significance is depicted on right panels.
2.3. Amino acid composition of CDR loops
1) Number of charged amino acids
To obtain a detailed picture of the molecular correlates that deter-
mine the physicochemical characteristics of Abs, we analyzed the num-
ber of different types of amino acid residues in CDR regions. We fo-
cused on CDR H3, CDR H2 and CDR L3 – the parts of antigen combin-
ing site characterized by the highest degree of sequence variability and/
or significance for antigen recognition. The correlation analyses demon-
strated that higher number of residues with positive charge (sum of Arg,
Lys and His) in CDR H3 is associated with a significantly elevated de-
gree of polyreactivity, as determined by ELISA and BVP assays (Fig. 1).
In contrast, the number of basic residues in CDR H2 and CDR L3 of the
Abs did not show significant contribution to the promiscuous antigen
recognition. It is noteworthy that there was no significant correlation
between the number of positively charged residues in CDR H3 and anti-
gen binding polyreactivity estimated by using the PSR assay. In contrast
to ELISA and BVP assays where antigens are immobilized to solid sup-
port, the PSR assay uses solubilized membrane preparations. The dense
surface immobilization of antigens may lead to affinity enhancement of
Abs via avidity effect. This result highlights the importance of the type
of technique for assessment of the Ab polyreactivity for evaluation of
the phenomenon.
Previous studies have also reported an association of elevated num-
ber of basic amino acid residues within CDR H3 loop with polyreactiv-
ity (Birtalan et al., 2008; Kelly et al., 2017; K. E. Tiller et al., 2017).
These studies implied that Arg is the main contributor to the promiscu-
ity of Abs. Our results, however, suggest that when analyzed individu-
ally, the number of arginine residues in CDR H3 did not significantly
contribute to binding promiscuity (Fig. 1). Our data are also in accor-
dance with a recent study, which used the same set of 137 Abs. The
study revealed that the overall sum of positive amino acids residues in
the six CDR loops predicts the lack of specificity and unfavorable behav-
ior of Abs (Rabia et al., 2019).
In addition to polyreactivity, we observed that basic amino acid
residues in CDR H3 significantly influence other biophysical features of
Abs. Thus, the propensity for self-association of IgG was significantly
correlated with the presence of Lys in CDR H3 (Fig. 1). Notably, Lys is
a constituent of CDR H3 sequence of 25 out of 137 studied Abs. More-
over, the presence of another basic amino acid – His - in CDR H3 was
associated with significantly lower expression yield in HEK cells. His
residues are rarely found in CDR loops of human Abs. Indeed, only 22
Abs from the studied repertoire contained at least one His in CDR H3.
The correlation of presence of His with expression yield may have im-
portant practical repercussions for development of Ab therapeutics. In-
terestingly, our statistical analyses also revealed a reverse correlation
of the number of positively charged residues in CDR H2 with the ten-
dency of Abs to interact with hydrophobic surfaces (HIC and SMAC as-
says) (Fig. 4). This result can be explained by the ability of charged
amino acids to screen out the hydrophobic patches on protein surface,
thus increasing overall solubility of Abs. These data also emphasized
that the principal contributor to the reduction of the hydrophobic in-
teractions and aggregation of Abs among the basic residues in CDR H2
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Fig. 4. Correlation of physicochemical parameters of therapeutic Abs with sequence traits of CDR H2. The heat map displays the values of correlation coefficient (ρ) obtained after Spear-
man’s rank-order analysis of the correlation of data from biophysical and antigen binding assays with the length of CDR H2; or number of particular amino acid residues in CDR H2. The
red signifies positive correlation, the blue negative. The summary of statistical significance is depicted on right panels.
is Arg (Fig. 4). Another association that appeared from statistical analy-
ses concerns the light chain of IgG. Thus, the presence of Arg residues
in CDR L3 has a significant negative impact on thermodynamic stabil-
ity of Fab regions. This finding is very intriguing since V⁠L is generally
considered less important for determining the global properties of Abs.
It would be interesting to investigate the molecular mechanisms of the
effect of Arg on Fab stability.
Contrary to the effects of basic amino acid residues in the CDR H3
and L3, our analyses did not show any impact of acidic amino acid
residues (Asp and Glu) on the physicochemical properties of the thera-
peutic Abs (Fig. 1 and 2). However, the presence of negatively charged
amino acids in CDR H2, significantly correlated with lower degree of
self-association and binding to polyclonal human IgG (AC-SINS, CIC
and CSI-BLI assays). In addition, higher number of negatively charged
residues in CDR H2 correlated with significantly lower expression titers
(Fig. 4); an effect contributed mainly by Asp. This observation once
again delineated unexpected but important role of CDR H2 region in
shaping the biophysical behavior of Abs. Notably, that amino acid
residues with negative charge were demonstrated to increase the sta-
bility of V regions. Thus, mutation to Asp or Glu at different positions
in CDR L2 and CDR H1 resulted in considerable augmentation of ther-
mostability of immunoglobulins (Dudgeon et al., 2012). Similar muta-
tions in CDR H2, however, did not have a positive impact on the stabil-
ity V region (Dudgeon et al., 2012). Nonetheless, our data underscore
the important role of amino acids with negative charge, when present
in other CDRs than H3 and L3, in determining the physicochemical
characteristics of Abs.
In conclusion, the analyses of the impact of charge amino acid
residues on physicochemical parameters and binding behavior of thera-
peutic monoclonal Abs confirmed some precedent observations, but also
revealed new relationships. In general, higher number of basic amino
acids in CDRs would have detrimental consequences for developability
of Abs. Acidic amino acids have considerably smaller influence on the
physicochemical characteristics of Abs. These data also revealed an im-
portant role of CDR H2 in regulating the properties of Abs. Both posi-
tively and negatively charged residues in this region have beneficial ef-
fect on Ab physicochemical characteristics.
2) Number of aromatic amino acids
Aromatic amino acid residues (Phe, Tyr, Trp) are key constituent
of the antigen combining sites of Abs (Mian et al., 1991; Sundberg
and Mariuzza, 2002; M. Wang et al., 2018). Our analyses revealed that
number of aromatic residues in CDR H3 positively correlates with in-
creased interaction of Abs to hydrophobic matrix or salt-induced aggre-
gation (HIC, SGAC-SINS, SMAC assay). In addition, the elevated num-
ber of aromatic residues in CDR H3 results in significantly higher po-
tential of the Abs to bind with polyclonal human IgG (Fig. 1). The cor-
relation analyses reveled similar effect of aromatic amino acid when
present in CDR H2 (Fig. 4). Conversely, no significant correlation of
number of aromatic residues in CDR L3 and any of studied physic-
ochemical parameters was determined. Interestingly, these analyses
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showed that the higher numbers of aromatic amino acids in CDR H2 is
associated with a reduced antigen binding polyreactivity (Fig. 4).
Further analyses of the role of individual aromatic amino acid
residues demonstrated that the main contributor to elevated hydropho-
bic interactions and aggregation of the Abs is the presence of Tyr
residues in CDR H3 and CDR H2 (Fig. 1 and Fig. 4). Of note, higher
number of Tyr in CDR H3 is also positively correlated with increased
homophilic binding of the monoclonal Abs (ACSINS assay, Fig. 1). The
number of Tyr residues in CDR H2 correlates with higher binding of the
Abs to human pooled IgG (CIC assay, Fig. 4) and a reduced polyreactiv-
ity (BVP assay, Fig. 4). In addition to Tyr, the presence of Trp residues
in CDR H3 is strongly correlated with augmented hydrophobic interac-
tions (HIC, SMAC and SGAC100 assays, Fig. 1). Furthermore, our analy-
ses indicated that the occurrence of Trp residues in CDR L3 is associated
with considerably lower thermodynamic stability of entire Fab fragment
(Fig. 2). When studied individually the higher number of Phe residues
in CDR H3 showed a significantly higher binding to polyclonal human
IgG (CIC assay, Fig. 1).
The observed contribution of aromatic amino acid residues in anti-
gen combining sites of Abs to hydrophobic interactions is not unex-
pected. Indeed, aromatic residues are characterized with highest hy-
drophobicity index among amino acids. Moreover, these residues are
abounded in Abs’ paratopes and are unusually exposed at the molecular
surface(Mian et al., 1991; Robin et al., 2014; Sundberg and Mariuzza,
2002; M. Wang et al., 2018). In a recent study, it was demonstrated that
the presence of motifs rich of Trp in CDR H3 is associated with a greater
degree of antigen binding promiscuity as assessed by PSR assay (Kelly et
al., 2018). This work was based on interrogation of single-chain variable
fragment libraries expressed on the surface of yeast cells. In the current
investigation we did not observe any discernable effect of Trp on the
polyreactivity of the therapeutic Abs. This might be explained by the
differences in the origin of analyzed Abs. Our study however is in full
accordance with previous works demonstrating the effect of Trp on an-
tibody hydrophobicity and self-aggregation (van der Kant et al., 2017;
Wang et al., 2009, 2010).
3) Number of polar amino acids
Next, we analyzed the impact of polar amino acid residues (sum of
the number of Cys, Tyr, Asn, Gln, Ser, and Thr) in the CDR loops on
different biophysical properties and on the antigen binding promiscuity
of the therapeutic Abs. These analyses indicated that an increased num-
ber of polar residues in CDR H3 correlates with a significantly higher
binding to hydrophobic matrix and IgG aggregation in solution (HIC and
SMAC assays, Fig. 1). On the other hand, an elevated number of polar
residues in CDR L3 is associated with a lower antigen binding polyre-
activity, assessed by BVP ELISA (Fig. 2). The overall number of polar
residues in CDR H2 has impact only on the ability of the therapeutic Abs
to recognize the human polyclonal IgG. Thus, higher number of polar
residues is associated with a higher degree of cross-reactivity to human
immunoglobulin (CIC assay, Fig. 4).
When studied individually the frequency of different polar amino
acids displayed intriguing effects on the biophysical properties of the
Abs. Thus, it was apparent that the main contributor for aggregation
and elevated hydrophobicity of therapeutic Abs is the presence of Tyr
in CDR H3 (Fig. 1). This amino acid has both aromatic and polar char-
acter. Most likely the contribution of Tyr towards hydrophobicity of
the Abs is due to its aromatic phenyl moiety. The correlation analyses
also suggested that the occurrence of Gln residues in CDR H3 is associ-
ated with a significantly higher level of antigen binding polyreactivity
(PSR and ELISA assays, Fig. 1). To the best of our knowledge this is the
first observation highlighting the role of Gln in the promiscuity of Abs.
Strikingly, Gln residues when localized in the CDR H2 showed a less
pronounced but still significant opposite effect on the polyreactivity of
the therapeutic Abs (PSR assay, Fig. 4). This result clearly implies that
the impact of distinct amino acids on the binding behavior of Abs
strongly depends on the molecular microenvironment.
The calculations indicated that Ser residues in CDR L3 determine
some of the biophysical properties of the therapeutic Abs. Thus, higher
number of Ser is associated with significantly lower thermodynamic sta-
bility of the Abs (Tm, Fig. 2). Additionally, Ser residues in CDR L3 lower
the threshold of salt-induced aggregation of the Abs (SGAC100 assay,
Fig. 2) and augment the homophilic interactions (ACSINS assay, Fig. 2).
Ser is one of the most abundant amino acid residues in the CDR loops
of human Abs (Robin et al., 2014; M. Wang et al., 2018). To the best of
our knowledge the number of this amino acid in CDRs has never been
associated with physicochemical properties of Abs. In addition, the pre-
sent study suggested that another polar amino acid residue in the CDR
L3 that has a global impact on Abs is Asn. More frequent occurrence of
Asn in CDR L3 of studied Abs is associated with a higher expression IgG
yield in HEK cells (Fig. 2). Collectively, these results once again high-
light the essential role of the light chain in determining overall proper-
ties of IgG molecule.
4) Number of hydrophobic amino acids
The amino acids with hydrophobic aliphatic side chains include –
Ala, Val, Leu, Ile, and Met. The overall number of these amino acids in
the CDRs had only minor role in determining the biophysical features
of the therapeutic Abs. Indeed, only three features of the studied Abs
were influenced by number of hydrophobic residues in CDR H3. Thus,
net number of hydrophobic residues in CDR H3 demonstrates a positive
correlation with the expression titer in HEK cells and with hydrophobic-
ity (SMAC assay, Fig. 1). Intriguingly, a higher occurrence of residues
with hydrophobic side chains in CDR H3 was also associated with re-
duced antigen binding promiscuity of the therapeutic Abs (PSR assay,
Fig. 1). The sum of aliphatic amino acids in CDR H2 and CDR L3 is not
linked with any of biophysical traits of the therapeutic Abs.
Assessment of the individual contributions of different hydrophobic
amino acids demonstrated that the presence of Val in CDR H3 is strongly
associated with higher expression titer of IgG in HEK cells (Fig. 1). Be-
sides Val, the number of Ile residues in CDR H3 also impacts positively
IgG expression (Fig. 1). Moreover, Ile residues significantly influenced
the accelerated stability of the Abs (AS assay, Fig. 1), antigen binding
promiscuity and the cross reactivity to polyclonal human IgG (PSR and
CIC assays, Fig. 1). Interestingly, these correlation analyses suggested
that the presence of Ile in CDR H3 results in a lower degree of binding
promiscuity.
The number of Val residues in CDR L3 also affects the Ab expression
levels but this effect is opposite to those observed with CDR H3 (Fig.
2). Our analyses showed that the number of Val residues in CDR H2 has
also a substantial impact on the thermodynamic stability and correlated
with lower storage stability (AS assay, Fig. 2) of the therapeutic Abs.
In addition, the correlation analyses revealed that the number of Leu
in the CDR H2 and in the CDR L3 loops is associated with significantly
augmented antigen binding promiscuity, as assessed by PSR and BVP as-
says (Fig. 2 and Fig. 4). Met residues in CDR L3 are also positively asso-
ciated with antigen binding promiscuity of the therapeutic Abs (ELISA
assay, Fig. 4). The role of aliphatic amino acid residues for antigen
binding polyreactivity of Abs has been already demonstrated. Thus, a
recent study has shown that polyreactive antibodies from a repertoire
of human scFv, expressed on surface of yeast have high frequency of
Val residues in their CDR H3 (Kelly et al., 2017). In our study we did
not find significant relationship of Val to the Ab polyreactivity but to
a structurally similar amino acid - Leu. Regardless of discrepancy, to-
gether both studies imply that certain aliphatic amino acid residues in
the antigen combining sites of Abs may determine the polyreactivity be-
havior.
5) Number of glycine and proline
Gly and Pro are unorthodox amino acids that have a considerable
impact on the conformation of polypeptide chains (Imai and Mitaku,
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2005; MacArthur and Thornton, 1991). Spearman's rank-order corre-
lation indicated that the presence of Gly in the CDR H3 of the stud-
ied Abs significantly correlated with increased hydrophobicity (HIC and
SMAC assays, Fig. 1). Moreover, the higher frequency of Gly in CDR
L3 is associated with an extended antigen binding polyreactivity of the
Abs (BVP assay, Fig. 2). A higher frequency of Pro residues in CDR H2
is associated with significantly augmented hydrophobicity of the Abs
(HIC assay, Fig. 2). The relationship between Gly and Ab hydrophobic-
ity and polyreactivity might be explained by an extension of the con-
formational dynamics of the CDR loops. The higher structural flexibility
of paratope would increase the probability of solvent exposure of hy-
drophobic residues or for adaptation of the paratope to structurally un-
related antigens.
2.4. Molecular modeling
To understand better how the observed correlations in the sequence
characteristics of therapeutic Abs influence overall configuration of
the antigen-combining site, we used Rosetta software for modeling of
three-dimensional structure of V regions. For these analyses we selected
only the Abs characterized by extremes in their polyreactivity. As it is
illustrated on Fig. 5, overall topology of the antigen binding sites of
the most polyreactive do not differ from highly specific Abs. All these
Abs have flat antigen binding sites appropriate for recognition of pro-
tein antigens. Nevertheless, there was a considerable difference in the
distribution of the electrostatic charges on the molecular surface (Fig.
5). All four most polyreactive antibodies have large patches of positively
charged molecular surface overlapping with the antigen-binding region.
In contrast, the antigen-binding surface of the modeled monoreactive
Abs have considerably balanced pattern of distribution of the electrosta-
tic charges. Importantly, the modeling result fully corroborate the corre-
lation analyses showing that the promiscuous Abs possess a higher num-
ber of positively charged amino acids in their CDRs, as observed in the
present study and by others (Rabia et al., 2019; Raybould et al., 2019).
2.5. Overall perspective and concluding remarks
Numerous studies have indicated that certain physicochemical char-
acteristics and binding properties of Abs determine their pharmaco-
kinetics and therapeutic efficacy in vivo. For example, it was demon
strated that Abs that have substantial basic charge on their antigen-com-
bining sites are characterized by accelerated clearance rates
(Datta-Mannan et al., 2015; Schoch et al., 2015). This can be partly ex-
plained by non-specific interactions with negatively charged peptido-
glycan matrix and by enhanced interaction with FcRn receptor at phys-
iological pH. Unfavorable pharmacokinetic profiles are observed also
for Abs with prominent antigen-binding promiscuity or a tendency for
self-association (Avery et al., 2018; Kelly et al., 2015).
Measurement of a panel of biophysical and binding characteristics
of therapeutic Abs undoubtedly would contribute to better quality as-
sessment and avoidance of investment in candidates with undesirable
pharmacological properties. However, it is equally important to develop
an understanding of the molecular origin of particular physiochemical
behavior of the Abs. To provide this information we evaluated the se-
quence correlates that determine the physicochemical properties and
the antigen binding behavior of a repertoire of 137 therapeutic mono-
clonal Abs.
The obtained data can help the fundamental understanding of im-
munoglobulin molecules, but also might have important practical reper-
cussions for development of Ab-based therapeutics. Some of the obser-
vations in the current work confirmed results from previous investiga-
tions with the same or other sets of Abs. For example, correlation be-
tween number of somatic mutations in V domains and antigen binding
promiscuity has already been demonstrated for other Abs. Similarly, the
present study corroborates data underlining the role of basic amino acid
residues in the CDRs in mediating Ab polyreactivity. These assenting
results support the reliability of the correlation analyses, regardless of
observed weak correlation coefficients (most frequently the correlation
coefficient with value below 0.35). The main advantage of the present
study however is that it provides a number of sequence correlates of V
domains that, to the best of our knowledge, have never been demon-
strated before. Thus, the correlation analyses strongly suggest that CDRs
with longer lengths and high content of aromatic residues drive aggre-
gation and self-association of the Abs. The analyses also revealed un-
expected contribution of the presence of Gln residues in CDR H3 and
H2 to polyreactivity. It is noteworthy that higher the number of acidic
residues in CDR H2 significantly reduces self-association of Abs. More-
over, distinct types of amino acid residues (His, Arg, Asp, Ser, Asn, Gln,
Val, Ile) were found to affect favorably or unfavorably the expression
titer and thermodynamic stability of the Abs.
Fig. 5. Surface electrostatic charges of antigen binding sites of monoreactive and polyreactive Abs. Top view of the structures of V regions of monoreactive (top row) and selected polyre-
active (bottom row). The selected polyreactive Abs demonstrated the most pronounced antigen binding promiscuity in three polyreactivity assessment assays. The electrostatic charges
(blue negative charge and red positive charge) were colored using Chimera software. The structural models of V regions were generated with ROSSIE online server.
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One of the most important findings in this study is that certain amino
acids have localization-dependent effects on the physicochemical attrib-
utes of the monoclonal Abs. This result points to the importance of the
molecular environment for defining the impact of a particular residue
type. The results stressed to the prominent role of CDR H2 in defining
overall properties of antibodies. This region of the V domain was over-
looked in most prior work.
The limitation of the present study is that it does not account for the
degree of surface exposure and concrete structural microenvironment of
amino acid. In this respect, a recent study provided description of struc-
ture- and context-dependent features of V region and defined five global
features of V regions that are critical for developability of the mono-
clonal therapeutic Abs (Raybould et al., 2019). Another drawback of our
analyses is that the studied Ab set is relatively small (137 molecules)
and consists of human, humanized and chimeric Abs. This may intro-
duce some bias in the data and therefore some of the conclusions should
be carefully validated in future work with large repertoires of entirely
human therapeutic Abs.
Nevertheless, the trends identified here by correlation analyses may
serve as guidelines for selection of therapeutic Ab candidates. For ex-
ample, the results suggest that avoidance of Abs with exceedingly long
CDR H3 or CDRs, containing high numbers of Gln, Tyr, and Arg, would
reduce the risk for selection of problematic Ab. Likewise, the knowledge
might be used for redemption of Abs with problematic behavior iden-
tified at late stage of development process. Combination of molecular
modeling and site-directed mutagenesis might be used for replacement
of amino acids with detriment impact on the developability of Abs. Our
study may also contribute to the development of more specific and con-
text-dependent analytical strategies for assessment of the developability
of Abs.
3. Methods
3.1. Correlation analyses
In their article Jain et al (T. Jain et al., 2017) provided raw data of
measurement obtained by 12 biophysical and binding assays (Supple-
ment). We obtained sequence information about the studied 137 mono-
clonal Abs from IMGT database (http://www.imgt.org/) and from study
of Jain et al (Jain et al., 2017). In few cases small mismatches between
V region amino acid sequences obtained from IMGT and those provided
in study of Jain were identified. However, these mismatches did not
bias our analyses. The estimation of the composition, and length of CDR
regions as well as number of amino acid replacements in V domains
was performed by IMGT Junction analysis tool. The biophysical measur-
able were correlated with different features of variable regions – num-
ber of somatic mutations in V⁠H and V⁠L domains, lengths of CDR H3, CDR
H2 and CDR L3, number of charged, polar, aromatic, and hydropho-
bic residues in the CDR regions, and frequency of individual amino acid
residues in CDR regions. The correlation analyses were performed by
non-parametric Spearman’s rank-order analysis using Graph Pad Prism
v.6 software (La Jolla, CA). A significant correlation was considered
only this with p value ≤ 0.05.
3.2. Modeling of variable regions of therapeutic antibodies
For modeling structures of the V regions of selected Abs we used se-
quence-based modeling algorithm - RosettaAntibody3 program (Marze
et al., 2016; Sivasubramanian et al., 2009; Weitzner and Gray, 2017;
Weitzner et al., 2017). The sequences of V regions were submitted to
ROSSIE online server (http://antibody.graylab.jhu.edu/) and computed
by using “true” CDR H3 option. Relaxed 3D models with lowest energy
were visualized by using Chimera UCSF Chimera package. Chimera is
developed by the Resource for Biocomputing, Visualization, and Infor
matics at the University of California, San Francisco (supported by
NIGMS P41-GM103311) (Pettersen et al., 2004).
Acknowledgments
We thank Dr Max Vasquez (Adimab) for critical reading of the man-
uscript and providing many constructive remarks. The work was sup-
ported by INSERM, France and by grants from “Fondation ARC pour la
recherche sur le cancer”, France (PJA 20171206410).
References
Avery, L.B., Wade, J., Wang, M., Tam, A., King, A., Piche-Nicholas, N., Kavosi, M.S., Penn,
S., Cirelli, D., Kurz, J.C., Zhang, M., Cunningham, O., Jones, R., Fennell, B.J., McDon-
nell, B., Sakorafas, P., Apgar, J., Finlay, W.J., Lin, L., Bloom, L., O’Hara, D.M., 2018.
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physico-
chemical properties related to favorable human pharmacokinetics. mAbs 10, 244–255.
Benckert, J., Schmolka, N., Kreschel, C., Zoller, M.J., Sturm, A., Wiedenmann, B., Warde-
mann, H., 2011. The majority of intestinal IgA+ and IgG+ plasmablasts in the human
gut are antigen-specific. J. Clin. Invest. 121, 1946–1955.
Birtalan, S., Zhang, Y., Fellouse, F.A., Shao, L., Schaefer, G., Sidhu, S.S., 2008. The intrin-
sic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity
of antibodies. J. Mol. Biol. 377, 1518–1528.
Datta-Mannan, A., Thangaraju, A., Leung, D., Tang, Y., Witcher, D.R., Lu, J., Wroblewski,
V.J., 2015. Balancing charge in the complementarity-determining regions of human-
ized mAbs without affecting pI reduces non-specific binding and improves the phar-
macokinetics. mAbs 7, 483–493.
Diebolder, C.A., Beurskens, F.J., de Jong, R.N., Koning, R.I., Strumane, K., Lindorfer, M.A.,
Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A.J., van de Winkel, J.G., Wilson, I.A.,
Koster, A.J., Taylor, R.P., Saphire, E.O., Burton, D.R., Schuurman, J., Gros, P., Parren,
P.W., 2014. Complement is activated by IgG hexamers assembled at the cell surface.
Science 343, 1260–1263.
Dimitrov, J.D., Planchais, C., Roumenina, L.T., Vassilev, T.L., Kaveri, S.V., Lacroix-Des-
mazes, S., 2013. Antibody polyreactivity in health and disease: statu variabilis. J. Im-
munol. 191, 993–999.
Dudgeon, K., Rouet, R., Kokmeijer, I., Schofield, P., Stolp, J., Langley, D., Stock, D.,
Christ, D., 2012. General strategy for the generation of human antibody variable
domains with increased aggregation resistance. Proc. Natl. Acad. Sci. U. S. A. 109,
10879–10884.
Imai, K., Mitaku, S., 2005. Mechanisms of secondary structure breakers in soluble proteins.
Biophysics 1, 55–65.
Jain, D., Salunke, D.M., 2019. Antibody specificity and promiscuity. Biochem. J. 476,
433–447.
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N.R., Nett, J.H., Sharkey, B., Bobrowicz, B.,
Caffry, I., Yu, Y., Cao, Y., Lynaugh, H., Brown, M., Baruah, H., Gray, L.T., Krauland,
E.M., Xu, Y., Vasquez, M., Wittrup, K.D., 2017. Biophysical properties of the clini-
cal-stage antibody landscape. Proc. Natl. Acad. Sci. U.S.A. 114, 944–949.
James, L.C., Roversi, P., Tawfik, D.S., 2003. Antibody multispecificity mediated by confor-
mational diversity. Science 299, 1362–1367.
Jarasch, A., Koll, H., Regula, J.T., Bader, M., Papadimitriou, A., Kettenberger, H., 2015.
Developability assessment during the selection of novel therapeutic antibodies. J.
Pharmaceut. Sci. 104, 1885–1898.
Jimenez, R., Salazar, G., Baldridge, K.K., Romesberg, F.E., 2003. Flexibility and molecular
recognition in the immune system. Proc. Natl. Acad. Sci. U. S. A. 100, 92–97.
Jimenez, R., Salazar, G., Yin, J., Joo, T., Romesberg, F.E., 2004. Protein dynamics and the
immunological evolution of molecular recognition. Proc. Natl. Acad. Sci. U. S. A. 101,
3803–3808.
Kang, C.Y., Cheng, H.L., Rudikoff, S., Kohler, H., 1987. Idiotypic self binding of a dom-
inant germline idiotype (T15). Autobody activity is affected by antibody valency. J.
Exp. Med. 165, 1332–1343.
Kang, C.Y., Kohler, H., 1986. Immunoglobulin with complementary paratope and idiotope.
J. Exp. Med. 163, 787–796.
Kaplon, H., Reichert, J.M., 2018. Antibodies to watch in 2018. mAbs 10, 183–203.
Kaplon, H., Reichert, J.M., 2018. Antibodies to watch in 2019. mAbs
Kaveri, S.V., Kang, C.Y., Kohler, H., 1990. Natural mouse and human antibodies bind to
a peptide derived from a germline VH chain. Evidence for evolutionary conserved
self-binding locus. J. Immunol. 145, 4207–4213.
Kelly, R.L., Le, D., Zhao, J., Wittrup, K.D., 2018. Reduction of nonspecificity motifs in syn-
thetic antibody libraries. J. Mol. Biol. 430, 119–130.
Kelly, R.L., Sun, T., Jain, T., Caffry, I., Yu, Y., Cao, Y., Lynaugh, H., Brown, M., Vasquez,
M., Wittrup, K.D., Xu, Y., 2015. High throughput cross-interaction measures for hu-
man IgG1 antibodies correlate with clearance rates in mice. mAbs 7, 770–777.
Kelly, R.L., Zhao, J., Le, D., Wittrup, K.D., 2017. Nonspecificity in a nonimmune human
scFv repertoire. mAbs 9, 1029–1035.
Kohli, N., Jain, N., Geddie, M.L., Razlog, M., Xu, L., Lugovskoy, A.A., 2015. A novel screen-
ing method to assess developability of antibody-like molecules. mAbs 7, 752–758.
Liu, Y., Caffry, I., Wu, J., Geng, S.B., Jain, T., Sun, T., Reid, F., Cao, Y., Estep, P., Yu, Y.,
Vasquez, M., Tessier, P.M., Xu, Y., 2014. High-throughput screening for developabil
9
UN
CO
RR
EC
TE
D
PR
OO
F
M. Lecerf et al. Molecular Immunology xxx (xxxx) xxx-xxx
ity during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
mAbs 6, 483–492.
MacArthur, M.W., Thornton, J.M., 1991. Influence of proline residues on protein confor-
mation. J. Mol. Biol. 218, 397–412.
Manivel, V., Bayiroglu, F., Siddiqui, Z., Salunke, D.M., Rao, K.V., 2002. The primary an-
tibody repertoire represents a linked network of degenerate antigen specificities. J.
Immunol. 169, 888–897.
Manivel, V., Sahoo, N.C., Salunke, D.M., Rao, K.V., 2000. Maturation of an antibody re-
sponse is governed by modulations in flexibility of the antigen-combining site. Immu-
nity 13, 611–620.
Marze, N.A., Lyskov, S., Gray, J.J., 2016. Improved prediction of antibody VL-VH orienta-
tion. Protein Eng. Des. Sel. 29, 409–418.
Meffre, E., Milili, M., Blanco-Betancourt, C., Antunes, H., Nussenzweig, M.C., Schiff, C.,
2001. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in
human B cell development. J. Clin. Invest. 108, 879–886.
Mian, I.S., Bradwell, A.R., Olson, A.J., 1991. Structure, function and properties of antibody
binding sites. J. Mol. Biol. 217, 133–151.
Nguyen, H.P., Seto, N.O., MacKenzie, C.R., Brade, L., Kosma, P., Brade, H., Evans, S.V.,
2003. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct.
Biol. 10, 1019–1025.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C.,
Ferrin, T.E., 2004. UCSF Chimera--a visualization system for exploratory research and
analysis. J. Comput. Chem. 25, 1605–1612.
Rabia, L.A., Zhang, Y., Ludwig, S.D., Julian, M.C., Tessier, P.M., 2019. Net charge of an-
tibody complementarity-determining regions is a key predictor of specificity. Protein
Eng. Des. Sel. https://doi.org/10.1093/protein/gzz002.
Raybould, M.I.J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A.P., Bujotzek,
A., Shi, J., Deane, C.M., 2019. Five computational developability guidelines for thera-
peutic antibody profiling. Proc. Natl. Acad. Sci. U.S.A. https://doi.org/10.1073/pnas.
1810576116.
Robin, G., Sato, Y., Desplancq, D., Rochel, N., Weiss, E., Martineau, P., 2014. Restricted
diversity of antigen binding residues of antibodies revealed by computational alanine
scanning of 227 antibody-antigen complexes. J. Mol. Biol. 426, 3729–3743.
Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., Emrich, T.,
2015. Charge-mediated influence of the antibody variable domain on FcRn-dependent
pharmacokinetics. Proc. Natl. Acad. Sci. U. S. A. 112, 5997–6002.
Sharma, V.K., Patapoff, T.W., Kabakoff, B., Pai, S., Hilario, E., Zhang, B., Li, C., Borisov,
O., Kelley, R.F., Chorny, I., Zhou, J.Z., Dill, K.A., Swartz, T.E., 2014. In silico selection
of therapeutic antibodies for development: viscosity, clearance, and chemical stabil-
ity. Proc. Natl. Acad. Sci. U. S. A. 111, 18601–18606.
Sivasubramanian, A., Sircar, A., Chaudhury, S., Gray, J.J., 2009. Toward high-resolution
homology modeling of antibody Fv regions and application to antibody-antigen dock-
ing. Proteins 74, 497–514.
Steinmeyer, D.E., McCormick, E.L., 2008. The art of antibody process development. Drug
Disc. Today 13, 613–618.
Sule, S.V., Sukumar, M., Weiss, W.Ft., Marcelino-Cruz, A.M., Sample, T., Tessier, P.M.,
2011. High-throughput analysis of concentration-dependent antibody self-association.
Biophys. J. 101, 1749–1757.
Sundberg, E.J., Mariuzza, R.A., 2002. Molecular recognition in antibody-antigen com-
plexes. Adv. Protein Chem. 61, 119–160.
Tiller, K.E., Li, L., Kumar, S., Julian, M.C., Garde, S., Tessier, P.M., 2017. Arginine mu-
tations in antibody complementarity-determining regions display context-dependent
affinity/specificity trade-offs. J. Biol. Chem. 292, 16638–16652.
Tiller, T., Tsuiji, M., Yurasov, S., Velinzon, K., Nussenzweig, M.C., Wardemann, H., 2007.
Autoreactivity in human IgG+ memory B cells. Immunity 26, 205–213.
van der Kant, R., Karow-Zwick, A.R., Van Durme, J., Blech, M., Gallardo, R., Seeliger, D.,
Assfalg, K., Baatsen, P., Compernolle, G., Gils, A., Studts, J.M., Schulz, P., Garidel, P.,
Schymkowitz, J., Rousseau, F., 2017. Prediction and reduction of the aggregation of
monoclonal antibodies. J. Mol. Biol. 429, 1244–1261.
Wang, M., Zhu, D., Zhu, J., Nussinov, R., Ma, B., 2018. Local and global anatomy of anti-
body-protein antigen recognition. J. Mol. Recognit. 31, e2693.
Wang, X., Das, T.K., Singh, S.K., Kumar, S., 2009. Potential aggregation prone regions in
biotherapeutics: a survey of commercial monoclonal antibodies. mAbs 1, 254–267.
Wang, X., Singh, S.K., Kumar, S., 2010. Potential aggregation-prone regions in comple-
mentarity-determining regions of antibodies and their contribution towards antigen
recognition: a computational analysis. Pharmaceut. Res. 27, 1512–1529.
Wardemann, H., Yurasov, S., Schaefer, A., Young, J.W., Meffre, E., Nussenzweig, M.C.,
2003. Predominant autoantibody production by early human B cell precursors. Sci-
ence 301, 1374–1377.
Weitzner, B.D., Gray, J.J., 2017. Accurate structure prediction of CDR H3 loops enabled
by a novel structure-based C-Terminal constraint. J. Immunol. 198, 505–515.
Weitzner, B.D., Jeliazkov, J.R., Lyskov, S., Marze, N., Kuroda, D., Frick, R., Adolf-Bryfogle,
J., Biswas, N., Dunbrack Jr, R.L., Gray, J.J., 2017. Modeling and docking of antibody
structures with Rosetta. Nat. Protoc. 12, 401–416.
Xu, Y., Roach, W., Sun, T., Jain, T., Prinz, B., Yu, T.Y., Torrey, J., Thomas, J., Bo-
browicz, P., Vasquez, M., Wittrup, K.D., Krauland, E., 2013. Addressing polyspeci-
ficity of antibodies selected from an in vitro yeast presentation system: a FACS-based,
high-throughput selection and analytical tool. Protein Eng. Des. Sel. 26, 663–670.
10
